Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Sell
20
GTBP Quote, Financials, Valuation and Earnings
Last price:
$0.75
Seasonality move
:
-5.56%
Day range:
$0.68 - $0.78
52-week range:
$0.54 - $3.85
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
59.35x
P/B ratio:
2.65x
Volume:
2.1M
Avg. volume:
2M
1-year change:
-67.99%
Market cap:
$7.9M
Revenue:
--
EPS (TTM):
-$3.40
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
GERN
Geron Corp.
|
$50.9M | -$0.05 | 7.03% | -8.38% | $3.60 |
|
LYEL
Lyell Immunopharma, Inc.
|
-- | -$2.30 | -100% | -1177.78% | $29.67 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.58 | 14.99% | 45.22% | $826.04 |
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$0.06 | -- | -30.48% | $6.83 |
|
XNCR
Xencor, Inc.
|
$30M | -$0.58 | -17.06% | -4.43% | $28.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
$0.75 | $8.00 | $7.9M | -- | $0.00 | 0% | 59.35x |
|
GERN
Geron Corp.
|
$1.31 | $3.60 | $836.2M | -- | $0.00 | 0% | 4.76x |
|
LYEL
Lyell Immunopharma, Inc.
|
$23.76 | $29.67 | $351.8M | -- | $0.00 | 0% | 86,158.63x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$733.04 | $826.04 | $77B | 17.55x | $0.88 | 0.48% | 5.67x |
|
SLS
SELLAS Life Sciences Group, Inc.
|
$3.98 | $6.83 | $677.7M | -- | $0.00 | 0% | -- |
|
XNCR
Xencor, Inc.
|
$12.79 | $28.83 | $913.3M | -- | $0.00 | 0% | 6.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
-- | -0.132 | 4.06% | 1.98x |
|
GERN
Geron Corp.
|
50.25% | 1.450 | 28.73% | 4.76x |
|
LYEL
Lyell Immunopharma, Inc.
|
13.89% | 1.210 | 22.07% | 10.03x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | -0.094 | 4.57% | 3.19x |
|
SLS
SELLAS Life Sciences Group, Inc.
|
1.3% | 0.623 | 0.3% | 7.50x |
|
XNCR
Xencor, Inc.
|
24.45% | 1.856 | 24.19% | 5.70x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
LYEL
Lyell Immunopharma, Inc.
|
-$2.6M | -$38.8M | -75.65% | -86.7% | -258960% | -$28.6M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$7.1M | -100.8% | -103.86% | -- | -$7.1M |
|
XNCR
Xencor, Inc.
|
$18.4M | -$47.5M | -15.54% | -20.07% | -226.29% | -$31M |
GT Biopharma, Inc. vs. Competitors
-
Which has Higher Returns GTBP or GERN?
Geron Corp. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -39.02%. GT Biopharma, Inc.'s return on equity of -626.24% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About GTBP or GERN?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 972.67%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 174.81%. Given that GT Biopharma, Inc. has higher upside potential than Geron Corp., analysts believe GT Biopharma, Inc. is more attractive than Geron Corp..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 GERNGeron Corp.3 1 1 -
Is GTBP or GERN More Risky?
GT Biopharma, Inc. has a beta of 1.172, which suggesting that the stock is 17.17% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.567%.
-
Which is a Better Dividend Stock GTBP or GERN?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or GERN?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. GT Biopharma, Inc.'s net income of -$3.1M is higher than Geron Corp.'s net income of -$18.4M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 4.76x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M GERNGeron Corp.4.76x -- $47.2M -$18.4M
-
Which has Higher Returns GTBP or LYEL?
Lyell Immunopharma, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -258973.33%. GT Biopharma, Inc.'s return on equity of -626.24% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M LYELLyell Immunopharma, Inc.-17006.67% -$2.13 $382.2M -
What do Analysts Say About GTBP or LYEL?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 972.67%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could grow by 24.86%. Given that GT Biopharma, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe GT Biopharma, Inc. is more attractive than Lyell Immunopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 LYELLyell Immunopharma, Inc.2 0 0 -
Is GTBP or LYEL More Risky?
GT Biopharma, Inc. has a beta of 1.172, which suggesting that the stock is 17.17% more volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GTBP or LYEL?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or LYEL?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Lyell Immunopharma, Inc. quarterly revenues of $15K. GT Biopharma, Inc.'s net income of -$3.1M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 86,158.63x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M LYELLyell Immunopharma, Inc.86,158.63x -- $15K -$38.8M
-
Which has Higher Returns GTBP or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of 38.89%. GT Biopharma, Inc.'s return on equity of -626.24% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About GTBP or REGN?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 972.67%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $826.04 which suggests that it could grow by 12.69%. Given that GT Biopharma, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe GT Biopharma, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is GTBP or REGN More Risky?
GT Biopharma, Inc. has a beta of 1.172, which suggesting that the stock is 17.17% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.
-
Which is a Better Dividend Stock GTBP or REGN?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or REGN?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. GT Biopharma, Inc.'s net income of -$3.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 5.67x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M REGNRegeneron Pharmaceuticals, Inc.5.67x 17.55x $3.8B $1.5B
-
Which has Higher Returns GTBP or SLS?
SELLAS Life Sciences Group, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of --. GT Biopharma, Inc.'s return on equity of -626.24% beat SELLAS Life Sciences Group, Inc.'s return on equity of -103.86%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M -
What do Analysts Say About GTBP or SLS?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 972.67%. On the other hand SELLAS Life Sciences Group, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 71.69%. Given that GT Biopharma, Inc. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe GT Biopharma, Inc. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 SLSSELLAS Life Sciences Group, Inc.2 0 0 -
Is GTBP or SLS More Risky?
GT Biopharma, Inc. has a beta of 1.172, which suggesting that the stock is 17.17% more volatile than S&P 500. In comparison SELLAS Life Sciences Group, Inc. has a beta of 2.262, suggesting its more volatile than the S&P 500 by 126.208%.
-
Which is a Better Dividend Stock GTBP or SLS?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. SELLAS Life Sciences Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or SLS?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than SELLAS Life Sciences Group, Inc. quarterly revenues of --. GT Biopharma, Inc.'s net income of -$3.1M is higher than SELLAS Life Sciences Group, Inc.'s net income of -$6.8M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while SELLAS Life Sciences Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus -- for SELLAS Life Sciences Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M
-
Which has Higher Returns GTBP or XNCR?
Xencor, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -28.7%. GT Biopharma, Inc.'s return on equity of -626.24% beat Xencor, Inc.'s return on equity of -20.07%.
Company Gross Margin Earnings Per Share Invested Capital GTBPGT Biopharma, Inc.-- -$0.83 $3M XNCRXencor, Inc.87.62% -$0.08 $827.7M -
What do Analysts Say About GTBP or XNCR?
GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 972.67%. On the other hand Xencor, Inc. has an analysts' consensus of $28.83 which suggests that it could grow by 125.44%. Given that GT Biopharma, Inc. has higher upside potential than Xencor, Inc., analysts believe GT Biopharma, Inc. is more attractive than Xencor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBPGT Biopharma, Inc.1 0 0 XNCRXencor, Inc.9 1 0 -
Is GTBP or XNCR More Risky?
GT Biopharma, Inc. has a beta of 1.172, which suggesting that the stock is 17.17% more volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.205%.
-
Which is a Better Dividend Stock GTBP or XNCR?
GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBP or XNCR?
GT Biopharma, Inc. quarterly revenues are --, which are smaller than Xencor, Inc. quarterly revenues of $21M. GT Biopharma, Inc.'s net income of -$3.1M is higher than Xencor, Inc.'s net income of -$6M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 6.29x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M XNCRXencor, Inc.6.29x -- $21M -$6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
